Other Events ·
TELA Bio stockholders approve reverse split range of 1-for-5 to 1-for-15 after Nasdaq compliance
TELATELA Bio, Inc.
TELA Bio, Inc. held a Special Meeting of Stockholders on October 8, 2026, where shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split with a ratio between one-for-five and one-for-fifteen. The Board retains sole discretion to set the exact ratio within this range. This approval follows receipt of a letter from Nasdaq on October 5, 2026, confirming that TELA Bio has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Consequently, the company does not intend to effect an immediate reverse stock split at this time. The vote was decisive, with approximately 30.5 million shares voting in favor against roughly 80,000 votes against. TELA Bio develops and commercializes medical devices for wound care and surgical applications.